1. Pulmonary Nocardiosis in an Immunocompetent Patient with Cystic Fibrosis. (15th April 2015) Authors: Schoen, Lucy; Santoro, Jonathan D.; Milla, Carlos; Bhargava, Sumit Other Names: Koizumi Tomonobu Academic Editor. Journal: Case reports in pulmonology Issue: Volume 2015(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults. Issue 1 (December 2018) Authors: Kim, Jeeyeon; Farahmand, Miesha; Dunn, Colleen; Milla, Carlos; Horii, Rina; Thomas, Ewart; Moss, Richard; Wine, Jeffrey Journal: Scientific reports Issue: Volume 8:Issue 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Issue 7 (July 2018) Authors: Rosenfeld, Margaret; Wainwright, Claire E.; Higgins, Mark; Wang, Linda T.; McKee, Charlotte; Campbell, Daniel; Tian, Simon; Schneider, Jennifer; Cunningham, Steve; Davies, Jane C.; Harris, William; Mogayzel, Peter; McCoy, Karen; Milla, Carlos; Rubenstein, Ronald; Walker, Seth; Black, Philip; Mont... Journal: Lancet Issue: Volume 6:Issue 7(2018) Page Start: 545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR. Issue 4 (20th November 2010) Authors: Sheridan, Molly B; Hefferon, Timothy W; Wang, Nulang; Merlo, Christian; Milla, Carlos; Borowitz, Drucy; Green, Eric D; Mogayzel, Peter J; Cutting, Garry R Journal: Journal of medical genetics Issue: Volume 48:Issue 4(2011) Page Start: 235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Issue 2 (29th September 2015) Authors: Shapiro, Adam J.; Zariwala, Maimoona A.; Ferkol, Thomas; Davis, Stephanie D.; Sagel, Scott D.; Dell, Sharon D.; Rosenfeld, Margaret; Olivier, Kenneth N.; Milla, Carlos; Daniel, Sam J.; Kimple, Adam J.; Manion, Michele; Knowles, Michael R.; Leigh, Margaret W. Journal: Pediatric pulmonology Issue: Volume 51:Issue 2(2016:Feb.) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care. Issue 12 (3rd September 2020) Authors: Brockmeyer, Jake M.; Wise, Russell T.; Burgener, Elizabeth B.; Milla, Carlos; Frymoyer, Adam Journal: Pediatric pulmonology Issue: Volume 55:Issue 12(2020) Page Start: 3343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndrome. Issue 6 (11th March 2016) Authors: Macmurdo, Colleen F.; Wooderchak‐Donahue, Whitney; Bayrak‐Toydemir, Pinar; Le, Jenny; Wallenstein, Matthew B.; Milla, Carlos; Teng, Joyce M. C.; Bernstein, Jonathan A.; Stevenson, David A. Journal: American journal of medical genetics Issue: Volume 170:Issue 6(2016) Page Start: 1450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Autonomous wearable sweat rate monitoring based on digitized microbubble detection. Issue 22 (21st October 2022) Authors: Lin, Haisong; Yu, Wenzhuo; Suarez, Jorge Emiliano De Dios; Athavan, Harish; Wang, Yibo; Yeung, Christopher; Lin, Shuyu; Sankararaman, Sriram; Milla, Carlos; Emaminejad, Sam Journal: Lab on a chip Issue: Volume 22:Issue 22(2022) Page Start: 4267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Issue 7 (July 2021) Authors: Chilvers, Mark A; Davies, Jane C; Milla, Carlos; Tian, Simon; Han, Zifei; Cornell, Alexandra G; Owen, Caroline A; Ratjen, Felix Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Issue 7 (July 2021) Authors: Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Ne... Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗